JSJyoti Shankar

Jyoti Shankar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jyoti Shankar has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Chi-Chen Hong

    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA

    5 shared publications
  • Elisa V. Bandera

    Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute , New Brunswick, NJ

    4 shared publications
  • Gary Zirpoli

    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA

    4 shared publications
  • Song Yao

    Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA

    4 shared publications
  • Melanie Ruszczyk

    Authors' Affiliations: Departments of Cancer Prevention and Control and Pathology, Roswell Park Cancer Institute, Buffalo; Icahn School of Medicine at Mount Sinai, New York, New York; University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; J. Craig Venter Institute, Rockville, Maryland; New Jersey State Cancer Registry, New Jersey Department of Health, Trenton; Rutgers Cancer Institute of New Jersey, New Brunswick; and Rutgers School of Public Health, Piscataway, New Jersey

    3 shared publications
  • Michelle Roberts

    Roswell Park Cancer Institute, Buffalo, NY

    3 shared publications

Latest Publications

  • Open Access

    HIV-exposure, early life feeding practices and delivery mode impacts on faecal bacterial profiles in a South African birth cohort

    by Shantelle Claassen-Weitz, Sugnet Gardner-Lubbe, Paul Nicol, Gerrit Botha, Stephanie Mounaud, Jyoti Shankar, William C Nierman, Nicola Mulder, Shrish Budree, Heather J. Zar, et al.

    There are limited data on meconium and faecal bacterial profiles from African infants and their mothers. We characterized faecal bacterial communities of infants and mothers participating in a South African birth cohort. Stool and meconium specimens were collected from 90 mothers and 107 infants at birth, and from a subset of 72 and 36 infants at 4–12 and 20–28 weeks of age, respectively. HIV-unexposed infants were primarily exclusively breastfed at 4–12 (49%, 26/53) and 20–28 weeks (62%, 16/26). In contrast, HIV-exposed infants were primarily exclusively formula fed at 4–12 (53%; 10/19) and 20–28 weeks (70%, 7/10). Analysis (of the bacterial 16S rRNA gene sequences of the V4 hypervariable region) of the 90 mother-infant pairs showed that meconium bacterial profiles [dominated by Proteobacteria (89%)] were distinct from those of maternal faeces [dominated by Firmicutes (66%) and Actinobacteria (15%)]. Actinobacteria predominated at 4–12 (65%) and 20–28 (50%) weeks. HIV-exposed infants had significantly higher faecal bacterial diversities at both 4–12 (p = 0.026) and 20–28 weeks (p = 0.002). HIV-exposed infants had lower proportions ofBifidobacterium(p = 0.010) at 4–12 weeks. Maternal faecal bacterial profiles were influenced by HIV status, feeding practices and mode of delivery. Further longitudinal studies are required to better understand how these variables influence infant and maternal faecal bacterial composition.


  • Insights into study design and statistical analyses in translational microbiome studies

    by Jyoti Shankar

    Research questions in translational microbiome studies are substantially more complex than their counterparts in basic science. Robust study designs with appropriate statistical analysis frameworks are pivotal to the success of these translational studies. This review considers how study designs can account for heterogeneous phenotypes by adopting representative sampling schemes for recruiting the study population and making careful choices about the control population. Advantages and limitations of 16S profiling and whole-genome sequencing, the two primary techniques for measuring the microbiome, are discussed followed by an overview of bioinformatic processing of high-throughput sequencing data from these measurements. Practical insights into the downstream statistical analyses including data processing and integration, variable transformations, and data exploration are provided. The merits of regularization and ensemble modeling for analyzing microbiome data are discussed along with a recommendation for selecting modeling approaches based on data-driven simulations and objective evaluation. The review builds on several recent discussions of study design issues in microbiome research but with a stronger emphasis on the downstream and often-ignored aspects of statistical analyses that are crucial for bridging the gap between basic science and translation.


  • Open Access

    A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

    by Colin J. Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, et al.

    Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher response levels. The involvement of genes (e.g., HLA-DRB1*1501) with high inter-individual variability in Copaxone’s mechanism of action (MoA) suggests the potential contribution of genetics to treatment response. This study aimed to identify genetic variants associated with Copaxone response in patient cohorts from late-phase clinical trials. Single nucleotide polymorphisms (SNPs) associated with high and low levels of response to Copaxone were identified using genome-wide SNP data in a discovery cohort of 580 patients from two phase III clinical trials of Copaxone. Multivariable Bayesian modeling on the resulting SNPs in an expanded discovery cohort with 1171 patients identified a multi-SNP signature of Copaxone response. This signature was examined in 941 Copaxone-treated MS patients from seven independent late-phase trials of Copaxone and assessed for specificity to Copaxone in 310 Avonex-treated and 311 placebo-treated patients, also from late-phase trials. A four-SNP signature consisting of rs80191572 (in UVRAG), rs28724893 (in HLA-DQB2), rs1789084 (in MBP), and rs139890339 (in ZAK(CDCA7)) was identified as significantly associated with Copaxone response. Copaxone-treated signature-positive patients had a greater reduction in annualized relapse rate (ARR) compared to signature-negative patients in both discovery and independent cohorts, an effect not observed in Avonex-treated patients. Additionally, signature-positive placebo-treated cohorts did not show a reduction in ARR, demonstrating the predictive as opposed to prognostic nature of the signature. A 10% subset of patients, delineated by the signature, showed marked improvements across multiple clinical parameters, including ARR, MRI measures, and higher proportion with no evidence of disease activity (NEDA). This study is the largest pharmacogenetic study in MS reported to date. Gene regions underlying the four-SNP signature have been linked with pathways associated with either Copaxone’s MoA or the pathophysiology of MS. The pronounced association of the four-SNP signature with clinical improvements in a ~10% subset of the MS patient population demonstrates the complex interplay of immune mechanisms and the individualized nature of response to Copaxone.


  • Open Access

    Differences in the Nasopharyngeal Microbiome During Acute Respiratory Tract Infection With Human Rhinovirus and Respiratory Syncytial Virus in Infancy

    by Christian Rosas-Salazar, Meghan H. Shilts, Andrey Tovchigrechko, Seth Schobel, James D. Chappell, Emma K. Larkin, Jyoti Shankar, Shibu Yooseph, Karen E. Nelson, Rebecca A. Halpin, et al.

    Respiratory viruses alter the nasopharyngeal microbiome and may be associated with a distinct microbial signature. To test this hypothesis, we compared the nasopharyngeal microbiome of 135 previously healthy infants with acute respiratory infection due to human rhinovirus (HRV; n = 52) or respiratory syncytial virus (RSV; n = 83). The nasopharyngeal microbiome was assessed by sequencing the V4 region of the 16S ribosomal RNA. Respiratory viruses were identified by quantitative reverse-transcription polymerase chain reaction. We found significant differences in the overall taxonomic composition and abundance of certain bacterial genera between infants infected with HRV and those infected with RSV. Our results suggest that respiratory tract viral infections are associated with different nasopharyngeal microbial profiles.


  • Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women

    by Ting-Yuan David Cheng, Jyoti Shankar, Gary Zirpoli, Michelle R. Roberts, Chi-Chen Hong, Elisa V. Bandera, Christine B. Ambrosone, Song Yao

    Purpose Positive energy imbalance and growth factors linked to obesity promote the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway. As the obesity–breast cancer associations differ between European American (EA) and African-American (AA) women, we investigated genetic variants in the mTOR pathway and breast cancer risk in these two racial groups. Methods We examined 400 single-nucleotide polymorphisms (SNPs) in 31 mTOR pathway genes in the Women’s Circle of Health Study with 1263 incident breast cancers (645 EA, 618 AA) and 1382 controls (641 EA, 741 AA). Multivariable logistic regression was performed separately within racial groups. Effect modification was assessed for measured body size and weight gain since age 20. Results In EA women, variants in FRAP1 rs12125777 (intron), PRR5L rs3740958 (synonymous coding), and CDKAL1 rs9368197 (intron) were associated with increased breast cancer risk, while variants in RPTOR rs9900506 (intron) were associated with decreased risk (nominal p-trend for functional and FRAP1 SNPs or p adjusted for correlated test [p ACT] < 0.05). For AA women, variants in RPTOR rs3817293 (intron), PIK3R1 rs7713645 (intron), and CDKAL1 rs9368197 were associated with decreased breast cancer risk. The significance for FRAP1 rs12125777 and RPTOR rs9900506 in EA women did not hold after correction for multiple comparisons. The risk associated with FRAP1 rs12125777 was higher among EAs who had body mass index ≥30 kg/m2 (odds ratio = 7.69, 95 % CI 2.11–28.0; p-interaction = 0.007) and gained weight ≥35 lb since age 20 (odds ratio = 3.34, 95 % CI 1.42–7.85; p-interaction = 0.021), compared to their counterparts. Conclusions The mTOR pathway may be involved in breast cancer carcinogenesis differently for EA and AA women.


  • Open Access

    Looking Beyond Respiratory Cultures: Microbiome-Cytokine Signatures of Bacterial Pneumonia and Tracheobronchitis in Lung Transplant Recipients

    by Jyoti Shankar, M Hong Nguyen, Maria M. Crespo, Eun J. Kwak, Sarah K. Lucas, Kevin J. McHugh, Stephanie Mounaud, John F. Alcorn, Joseph M. Pilewski, Norihisa Shigemura, et al.


  • Open Access

    Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene

    by Seth A. Schobel, Karla M. Stucker, Martin L. Moore, Larry J. Anderson, Emma K. Larkin, Jyoti Shankar, Jayati Bera, Vinita Puri, Meghan H. Shilts, Christian Rosas-Salazar, et al.

    Respiratory Syncytial Virus (RSV) is responsible for considerable morbidity and mortality worldwide and is the most important respiratory viral pathogen in infants. Extensive sequence variability within and between RSV group A and B viruses and the ability of multiple clades and sub-clades of RSV to co-circulate are likely mechanisms contributing to the evasion of herd immunity. Surveillance and large-scale whole-genome sequencing of RSV is currently limited but would help identify its evolutionary dynamics and sites of selective immune evasion. In this study, we performed complete-genome next-generation sequencing of 92 RSV isolates from infants in central Tennessee during the 2012–2014 RSV seasons. We identified multiple co-circulating clades of RSV from both the A and B groups. Each clade is defined by signature N- and O-linked glycosylation patterns. Analyses of specific RSV genes revealed high rates of positive selection in the attachment (G) gene. We identified RSV-A viruses in circulation with and without a recently reported 72-nucleotide G gene sequence duplication. Furthermore, we show evidence of convergent evolution of G gene sequence duplication and fixation over time, which suggests a potential fitness advantage of RSV with the G sequence duplication.


  • Leveraging transcriptomic data to pinpoint mechanisms of gemcitabine resistance and potential combination therapies for pancreatic cancer.

    by Rebecca L. Kusko, Yoonjeong Cha, Joseph Perez-Rogers, Nacho Caballero, Gregory Koytiger, Jyoti Shankar, Andrew Lysaght, Brian Weiner, Sarah Kolitz, Fadi Towfic, et al.

    E15730 Background: Pancreatic cancer has an estimated 5-year survival rate of only 5-6% and is often diagnosed after metastasis has occurred. Gemcitabine or gemcitabine combination therapies are frequently utilized, although existing gemcitabine combination therapies are highly toxic. The minimal effectiveness of current treatment options for pancreatic cancer precipitates the urgent unmet clinical need for promising novel combination therapies to enhance the efficacy of gemcitabine. Methods: In order to interrogate targetable mechanisms which orchestrate gemcitabine resistance, we analyzed transcriptomic data from three pancreatic cancer cell line datasets: (Klijn et al(N = 14), Collisson et al(N = 11), and CCLE(N = 12). After data processing and filtering low quality samples, a t-test was leveraged to identify genes differentially expressed (DE) between cell lines that are sensitive to gemcitabine vs resistant to gemcitabine as dictated by IC50 values reported in Collisson et al. Results: The overlap of DE genes between all three studies revealed 41 genes upregulated and 29 genes downregulated in gemcitabine resistant cell lines. Enrichment of genes upregulated in resistant cell lines includes WikiPathways ErbB signaling pathway (p = 0.006), Reactome G1 Phase (p = 0.002), and GO negative regulation of protein serine/threonine kinase activity (p = 0.004). Enrichment of genes downregulated in resistant cell lines includes WikiPathways Wnt signaling pathway (p = 0.02), and GO cell morphogenesis involved in differentiation (p = 9E-5). DE of putative drivers of resistance was validated using qRT-PCR, and expression changes after gemcitabine treatment was evaluated with FACS. Conclusions: Analysis to identify drugs which may reverse this signature of gemcitabine resistance is ongoing, and additional experimental studies are underway to substantiate key targets. By elucidating a robust and consistent signature distinguishing gemcitabine resistant from gemcitabine sensitive pancreatic cancer cell lines, we have pinpointed numerous genes and pathways which could be targeted by a potential combination therapy.

  • Microbial Communities and Cytokine Responses Associated With Respiratory Tract Infections Following Lung Transplant (LTx)

    by C. Clancy, J. Shankar, M. Crespo, J. Pilewski, C. Bermudez, W. Nierman, M. Nguyen

  • Open Access

    Using Bayesian modelling to investigate factors governing antibiotic-induced Candida albicans colonization of the GI tract

    by Jyoti Shankar, Norma V. Solis, Stephanie Mounaud, Sebastian Szpakowski, Hong Liu, Liliana Losada, William C. Nierman, Scott G. Filler

    Receipt of broad-spectrum antibiotics enhances Candida albicans colonization of the GI tract, a risk factor for haematogenously-disseminated candidiasis. To understand how antibiotics influence C. albicans colonization, we treated mice orally with vancomycin or a combination of penicillin, streptomycin and gentamicin (PSG) and then inoculated them with C. albicans by gavage. Only PSG treatment resulted in sustained, high-level GI colonization with C. albicans. Furthermore, PSG reduced bacterial diversity in the colon much more than vancomycin. Both antibiotic regimens significantly reduced IL-17A, IL-21, IL-22 and IFN-γ mRNA levels in the terminal ileum but had limited effect on the GI fungal microbiome. Through a series of models that employed Bayesian model averaging, we investigated the associations between antibiotic treatment, GI microbiota and host immune response and their collective impact on C. albicans colonization. Our analysis revealed that bacterial genera were typically associated with either C. albicans colonization or altered cytokine expression but not with both. The only exception was Veillonella, which was associated with both increased C. albicans colonization and reduced IL-21 expression. Overall, antibiotic-induced changes in the bacterial microbiome were much more consistent determinants of C. albicans colonization than either the GI fungal microbiota or the GI immune response.